Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) in chronic or accelerated phase, defined as having any of the following:
• •* Peripheral blood (PB) or bone marrow (BM) blasts at least 10% but less than 30%
• •* PB or BM blasts and promyelocytes at least 20%
• •* PB or BM basophils at least 20%
• •* Progressive splenomegaly (at least 10 cm confirmed twice at least 4 weeks apart or 50% increase in splenomegaly over 4 weeks)
• •* Clonal evolution defined as the presence of additional cytogenetic abnormalities other than the Ph chromosome
• •* Thrombocytopenia (platelet count less than 100,000/mm\^3) unrelated to therapy
• •* Hemoglobin less than 7 g/dL unrelated to therapy or bleeding
• •Failed prior treatment with imatinib mesylate or intolerant, unable, or unwilling to receive it
• •Ineligible for higher-priority or higher-efficacy regimens or protocols
• •No blastic phase CML
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •Eastern Cooperative Oncology Group (ECOG) 0-2
• •Life expectancy:
• •At least 18 weeks
• •Hematopoietic:
• •See Disease Characteristics
• •Hepatic:
• •Bilirubin no greater than 1.5 mg/dL
• •Renal:
• •Creatinine no greater than 1.5 mg/dL OR
• •Creatinine clearance greater than 60 mL/min
• •Other:
• •No other concurrent illness that would preclude study entry
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •No more than 2 prior cytotoxic regimens in addition to imatinib mesylate and/or hydroxyurea
• •At least 4 weeks since prior chemotherapy and recovered
• •Concurrent hydroxyurea and/or anagrelide allowed during first 2 courses
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy and recovered
• •Surgery:
• •Not specified
• •Other:
• •See Disease Characteristics
• •See Chemotherapy
• •At least 24 hours since prior imatinib mesylate
• •No other concurrent investigational agents